Depression is among the most disabling conditions in our society. According to the World Health Organization, depression is the leading cause of ill health and disability worldwide. In America, 12.5% of individuals over the age of 12 have filled an antidepressant prescription. Yet, the effectiveness of these medications are still lacking. Many patients don’t respond to antidepressant medications, and it can take months for the medicine to kick in. Unfortunately, many patients will regain their depression after being on medications long term.
Obsessive-compulsive disorder (OCD) is a chronic condition affecting 1 in 40 adults and 1 in 100 children in the United States. This disorder is characterized by intrusive, repetitive thoughts and behaviors. Interfering with work, interpersonal relationships, and in general, patients’ enjoyment of life, OCD can have a devastating effect due to its debilitating nature. The only FDA approved treatment for OCD are serotonin reuptake inhibitors (SRIs), but the effects of these are limited. Meaningful improvement can take up to 6 to 10 weeks and symptom relief is limited. To find a better way to treat this disorder, researchers at Columbia University conducted a study involving ketamine infusions.